Evidence map›Paper›PMID 27432282›Full record

ArticleScientific reports2016

FNDC5 expression and circulating irisin levels are modified by diet and hormonal conditions in hypothalamus, adipose tissue and muscle.

B M Varela-Rodríguez, L Pena-Bello, P Juiz-Valiña, B Vidal-Bretal, F Cordido, S Sangiao-Alvarellos

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 108 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Therapeutic Potential of Irisin in Neurodegenerative Diseases.International journal of molecular sciences · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Irisin, an Effective Treatment for Cardiovascular Diseases?Journal of cardiovascular development and disease · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

B M Varela-RodríguezDepartment of Medicine, School of Health Science, University of A Coruña, Campus de Oza, 15006, Spain.
L Pena-BelloDepartment of Medicine, School of Health Science, University of A Coruña, Campus de Oza, 15006, Spain.
P Juiz-ValiñaDepartment of Medicine, School of Health Science, University of A Coruña, Campus de Oza, 15006, Spain.
B Vidal-BretalDepartment of Medicine, School of Health Science, University of A Coruña, Campus de Oza, 15006, Spain.
F CordidoDepartment of Medicine, School of Health Science, University of A Coruña, Campus de Oza, 15006, Spain.
S Sangiao-AlvarellosDepartment of Medicine, School of Health Science, University of A Coruña, Campus de Oza, 15006, Spain.
Universidade da Coruña · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irisin is processed from fibronectin type III domain-containing protein 5 (FNDC5). However, a controversy exists concerning irisin origin, regulation and function. To elucidate the relationship between serum irisin and FNDC5 mRNA expression levels, we evaluated plasma irisin levels and FNDC5 gene expression in the hypothalamus, gastrocnemius muscle and different depots of adipose tissue in models of altered metabolism. In normal rats, blood irisin levels diminished after 48-h fast and with leptin, insulin and alloxan treatments, and serum irisin concentrations increased in diabetic rats after insulin treatment and acute treatments of irisin increased blood insulin levels. No changes were observed during long-term experiments with different diets. We suggested that levels of circulating irisin are the result of the sum of the irisin produced by different depots of adipose tissue and skeletal muscle. This study shows for the first time that there are differences in FNDC5 expression depending on white adipose tissue depots. Moreover, a considerable decrease in visceral and epididymal adipose tissue depots correlated with increased FNDC5 mRNA expression levels, probably in an attempt to compensate the decrease that occurs in their mass. Hypothalamic FNDC5 expression did not change for any of the tested diets but increased with leptin, insulin and metformin treatments suggesting that the regulation of central and peripheral FNDC5/irisin expression and functions are different.

Indexed as

Adipose TissueAnimalsDiabetes Mellitus, ExperimentalDietFibronectinsHumansHypothalamusLeptinMuscle, SkeletalObesityRatsTissue DistributionFibronectinsFNDC5 protein, humanFNDC5 protein, ratLeptin

Identifiers

PMID27432282
PMCPMC4949437
OpenAlexW2479341738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.